Page last updated: 2024-10-30

lansoprazole and Supranuclear Palsy, Progressive

lansoprazole has been researched along with Supranuclear Palsy, Progressive in 1 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Supranuclear Palsy, Progressive: A degenerative disease of the central nervous system characterized by balance difficulties; OCULAR MOTILITY DISORDERS (supranuclear ophthalmoplegia); DYSARTHRIA; swallowing difficulties; and axial DYSTONIA. Onset is usually in the fifth decade and disease progression occurs over several years. Pathologic findings include neurofibrillary degeneration and neuronal loss in the dorsal MESENCEPHALON; SUBTHALAMIC NUCLEUS; RED NUCLEUS; pallidum; dentate nucleus; and vestibular nuclei. (From Adams et al., Principles of Neurology, 6th ed, pp1076-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fawaz, MV1
Brooks, AF1
Rodnick, ME1
Carpenter, GM1
Shao, X1
Desmond, TJ1
Sherman, P1
Quesada, CA1
Hockley, BG1
Kilbourn, MR1
Albin, RL1
Frey, KA1
Scott, PJ1

Other Studies

1 other study available for lansoprazole and Supranuclear Palsy, Progressive

ArticleYear
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.
    ACS chemical neuroscience, 2014, Aug-20, Volume: 5, Issue:8

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autoradiography; Brain; Carbon Radioisotopes; Dru

2014